Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 17 10 2020
accepted: 21 01 2021
entrez: 15 3 2021
pubmed: 16 3 2021
medline: 29 6 2021
Statut: epublish

Résumé

The benefit of autologous stem cell transplantation (ASCT) in newly diagnosed myeloma patients, apart from supporting high dose chemotherapy, may include effects on T cell function in the bone marrow (BM). We report our exploratory findings on marrow infiltrating T cells early post-ASCT (day+100), examining phenotype and T cell receptor (TCR) repertoire, seeking correlations with timing of relapse. Compared to healthy donors (HD), we observed an increase in regulatory T cells (CD4+FoxP3+, Tregs) with reduction in CD4 T cells, leading to lower CD4:8 ratios. Compared to paired pre-treatment marrow, both CD4 and CD8 compartments showed a reduction in naïve, and increase in effector memory subsets, suggestive of a more differentiated phenotype. This was supported by increased levels of several immune-regulatory and activation proteins (ICOS, PD-1, LAG-3, CTLA-4 and GzmB) when compared with HD. Unsupervised analysis identified a patient subgroup with shorter PFS (p=0.031) whose BM contained increased Tregs, and higher immune-regulatory markers (ICOS, PD-1, LAG-3) on effector T cells. Using single feature analysis, higher frequencies of marrow PD-1+ on CD4+FoxP3- cells and Ki67+ on CD8 cells were independently associated with early relapse. Finally, studying paired pre-treatment and post-ASCT BM (n=5), we note reduced abundance of TCR sequences at day+100, with a greater proportion of expanded sequences indicating a more focused persistent TCR repertoire. Our findings indicate that, following induction chemotherapy and ASCT, marrow T cells demonstrate increased activation and differentiation, with TCR repertoire focusing. Pending confirmation in larger series, higher levels of immune-regulatory proteins on T cell effectors at day+100 may indicate early relapse.

Identifiants

pubmed: 33717112
doi: 10.3389/fimmu.2021.618610
pmc: PMC7946836
doi:

Substances chimiques

Biomarkers 0
Receptors, Immunologic 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

618610

Subventions

Organisme : Medical Research Council
ID : MR/S001883/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C416/A25145
Pays : United Kingdom

Informations de copyright

Copyright © 2021 Lee, Alrasheed, Khandelwal, Fitzsimons, Richards, Wilson, Chavda, Henry, Conde, De Massy, Chin, Galas-Filipowicz, Herrero, Chain, Quezada and Yong.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Leuk Lymphoma. 2015;56(9):2668-73
pubmed: 25573201
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Front Immunol. 2017 Apr 13;8:430
pubmed: 28450864
Cell. 2019 Feb 7;176(4):775-789.e18
pubmed: 30595452
Nat Med. 2019 Oct;25(10):1549-1559
pubmed: 31591606
Leuk Lymphoma. 2009 Nov;50(11):1860-4
pubmed: 19883313
Blood. 2012 Jan 19;119(3):687-91
pubmed: 22128143
N Engl J Med. 2017 Apr 6;376(14):1311-1320
pubmed: 28379796
J Clin Invest. 2019 Jan 2;129(1):106-121
pubmed: 30300141
J Exp Med. 2016 Aug 22;213(9):1799-818
pubmed: 27481131
J Immunol. 2013 May 1;190(9):4899-909
pubmed: 23536636
Cancer Cell. 2018 Apr 9;33(4):634-648.e5
pubmed: 29551594
Cell Oncol (Dordr). 2018 Feb;41(1):1-11
pubmed: 28994018
Bioinformatics. 2013 Mar 1;29(5):542-50
pubmed: 23303508
J Clin Invest. 2014 Mar;124(3):1168-72
pubmed: 24531550
Biol Blood Marrow Transplant. 2006 Aug;12(8):837-44
pubmed: 16864054
Blood. 2018 Oct 18;132(16):1675-1688
pubmed: 30154111
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
Int Immunol. 2018 Feb 3;30(1):13-22
pubmed: 29294043
Cancer Immunol Res. 2016 Jan;4(1):61-71
pubmed: 26464015
J Clin Invest. 2018 Jun 1;128(6):2487-2499
pubmed: 29558366
Lancet Haematol. 2016 Jul;3(7):e306-7
pubmed: 27374462
Bone Marrow Transplant. 2001 Oct;28(7):673-80
pubmed: 11704790
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Semin Immunol. 2007 Oct;19(5):318-30
pubmed: 18023361
Int J Clin Exp Med. 2015 Feb 15;8(2):1803-13
pubmed: 25932108
Semin Immunol. 2016 Feb;28(1):28-34
pubmed: 26976826
Clin Cancer Res. 2020 Jul 1;26(13):3443-3454
pubmed: 32220887

Auteurs

Lydia Lee (L)

Research Department of Hematology, Cancer Institute, University College London, London, United Kingdom.

Nouf Alrasheed (N)

Research Department of Hematology, Cancer Institute, University College London, London, United Kingdom.

Garima Khandelwal (G)

Bill Lyons Informatics Centre, Cancer Institute, University College London, London, United Kingdom.

Evelyn Fitzsimons (E)

Research Department of Hematology, Cancer Institute, University College London, London, United Kingdom.

Huw Richards (H)

Research Department of Hematology, Cancer Institute, University College London, London, United Kingdom.

William Wilson (W)

Cancer Research UK & UCL Cancer Trials Centre, London, United Kingdom.

Selina J Chavda (SJ)

Research Department of Hematology, Cancer Institute, University College London, London, United Kingdom.

Jake Henry (J)

Research Department of Hematology, Cancer Institute, University College London, London, United Kingdom.
Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London, United Kingdom.

Lucia Conde (L)

Bill Lyons Informatics Centre, Cancer Institute, University College London, London, United Kingdom.

Marc Robert De Massy (MR)

Research Department of Hematology, Cancer Institute, University College London, London, United Kingdom.
Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London, United Kingdom.
Department of Immunology, University College London, London, United Kingdom.

Melody Chin (M)

Research Department of Hematology, Cancer Institute, University College London, London, United Kingdom.

Daria Galas-Filipowicz (D)

Research Department of Hematology, Cancer Institute, University College London, London, United Kingdom.

Javier Herrero (J)

Bill Lyons Informatics Centre, Cancer Institute, University College London, London, United Kingdom.

Benny Chain (B)

Department of Immunology, University College London, London, United Kingdom.

Sergio A Quezada (SA)

Research Department of Hematology, Cancer Institute, University College London, London, United Kingdom.
Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London, United Kingdom.

Kwee Yong (K)

Research Department of Hematology, Cancer Institute, University College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH